Selected article for: "acute respiratory and additional day"

Author: Badu, Kingsley; Oyebola, Kolapo; Zahouli, Julien Z. B.; Fagbamigbe, Adeniyi Francis; de Souza, Dziedzom K.; Dukhi, Natisha; Amankwaa, Ebenezer F.; Tolba, Mai F.; Sylverken, Augustina A.; Mosi, Lydia; Mante, Priscilla Kolibea; Matoke-Muhia, Damaris; Goonoo, Nowsheen
Title: SARS-CoV-2 Viral Shedding and Transmission Dynamics: Implications of WHO COVID-19 Discharge Guidelines
  • Cord-id: 6yk9osnv
  • Document date: 2021_6_17
  • ID: 6yk9osnv
    Snippet: The evolving nature of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has necessitated periodic revisions of COVID-19 patient treatment and discharge guidelines. Since the identification of the first COVID-19 cases in November 2019, the World Health Organization (WHO) has played a crucial role in tackling the country-level pandemic preparedness and patient management protocols. Among others, the WHO provided a guideline on the clinical management of COVID-19 patients according
    Document: The evolving nature of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has necessitated periodic revisions of COVID-19 patient treatment and discharge guidelines. Since the identification of the first COVID-19 cases in November 2019, the World Health Organization (WHO) has played a crucial role in tackling the country-level pandemic preparedness and patient management protocols. Among others, the WHO provided a guideline on the clinical management of COVID-19 patients according to which patients can be released from isolation centers on the 10th day following clinical symptom manifestation, with a minimum of 72 additional hours following the resolution of symptoms. However, emerging direct evidence indicating the possibility of viral shedding 14 days after the onset of symptoms called for evaluation of the current WHO discharge recommendations. In this review article, we carried out comprehensive literature analysis of viral shedding with specific focus on the duration of viral shedding and infectivity in asymptomatic and symptomatic (mild, moderate, and severe forms) COVID-19 patients. Our literature search indicates that even though, there are specific instances where the current protocols may not be applicable ( such as in immune-compromised patients there is no strong evidence to contradict the current WHO discharge criteria.

    Search related documents:
    Co phrase search for related documents
    • active replication and adaptive immune response: 1, 2
    • active replication and adaptive response: 1, 2
    • active replication and live virus: 1, 2, 3, 4
    • actively infect and acute phase: 1
    • acute phase and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and adaptive response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and live virus: 1, 2, 3, 4, 5, 6
    • acute phase and load impact: 1, 2
    • adaptive immune response and live virus: 1, 2, 3
    • adaptive response and live virus: 1, 2, 3, 4
    • additional hour and live virus: 1